Trend of cervical cancer mortality in Belgium (1954-1994): Tentative solution for the certification problem of unspecified uterine cancer

International Journal of Cancer

Volumn 102, Issue 6, 2002, Pages 649-654

  Arbyn, Marc ^a   Geys, Helena ^b  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

Author keywords

Cervical cancer; Death certificate; Mortality; Trend analysis

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BELGIUM; CANCER MORTALITY; CANCER SCREENING; COHORT ANALYSIS; CONTROLLED STUDY; DEATH CERTIFICATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BELGIUM; DEATH CERTIFICATES; FEMALE; HUMANS; MIDDLE AGED; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; UTERINE NEOPLASMS;

EID: 0037146762     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10761     Document Type: Article

References (67)

1. Vyslouzilova S, Arbyn M, Van Oyen H, Drieskens S, Quataert P. Cervical cancer mortality in Belgium, 1955-1989. A descriptive study. Eur J Cancer 1997;33:1841-5.
2. Kelson M, Farebrother M. The effect of inaccuracies in death certification and coding practices in the European Economic Community (EEC) on international cancer mortality statistics. Int J Epidemiol 1987;16:411-4.
3. Percy C, Stanek E, Gloeckler L. Accuracy of cancer death certificates and its effect on cancer mortality statistics. Am J Public Health 1981;71:242-50.
4. Jenssen OM, Estève J, Moller H, Renard H. Cancer in the European Community and its member states. Eur J Cancer 1990;26:1167-256.
5. Arbyn M. Trend analysis of mortality from cervical in the Flemish region (1969-1997) [in Dutch]. In: Aelvoet W, Cloots H, eds. Gezondheidindicatoren 1998. Brussels: Ministerie van de Vlaamse Gemeenschap, 2000. 98-114.
6. Clayton D, Schiffiers E. Models for temporal variation in cancer rates. I: Age-period and age-cohort models. Stat Med 1987;6:449-67.
7. Clayton D, Schifflers E. Models for temporal variation in cancer rates. II: Age-period-cohort models. Stat Med 1987;6:469-81.
8. Waterhouse JAH, Muir CS, Shanmugaratnam K, eds. Cancer Incidence in Five Continents. Lyon: IARC, 1976.
9. Doll R, Smith PG. Comparison between registries: Age-standardised rates. In: Waterhouse JAH, Muir CS, Shanmugaratnam K, Powell J, eds. Cancer Incidence in Five Continents. vol. 4. Lyon: IARC, 1982. 671-5.
10. Estève J, Benhamou E, Raymond L. Statistical Methods in Cancer Research. Descriptive Epidemiology. Vol. 4. Lyon: IARC, 1994.
11. Moolgavkar SH. Analysis of vital statistics data. In: Rothman KJ, Greenland S, eds. Modern Epidemiology. Philadelphia: Lippincott-Raven, 1998. 481-97.
12. Arbyn M, Van Oyen H, Sartor F, Tibaldi F, Molenberghs G. Description of the influence of age, period and cohort effects on cervical cancer mortality by log linear Poisson models (Belgium, 1955-94). Arch Public Health 2002;60:73-100.
13. Kupper LL, Janis JM, Karmous A, Greenberg BG. Statistical age-period cohort analysis: A review and critique. J Chronic Dis 1985;38:811-30.
14. Beral V. Cancer of the cervix: A sexually transmitted infection? Lancet 1974;1:1037-40.
15. Osmond C, Gardner MJ. Age, period and cohort models applied to cancer mortality rates. Stat Med 1982;1:245-59.
16. Ebeling K, Nischan P. Organization and Results of Cervical Cancer Screening in the German Democratic Republic. IARC Sci Publ 76. Lyon: IARC, 1986. 251-66.
17. Miller AB, Visentin T, Howe GR. The effect of hysterectomies and screening on mortality from cancer of the uterus in Canada. Int J Cancer 1981;27:651-7.
18. Arbyn M, Quataert P, Van Hal G, Van Oyen H. Cervical cancer screening in the Flemish region (Belgium): Measurement of the attendance rate by telephone interview. Eur J Cancer Prev 1997;6:389-98.
19. Centrum voor Operationeel Onderzoek en Volksgezondheid. Mortality and Cause-Specific Mortality in the Flemish Community, 1989-91 [in Dutch]. Brussels: Ministerie Vlaamse Gemeenschap, Administratie van Volksgezondheid van de Vlaamse Gemeenschap, Wetenschappelijk Instituut voor Volksgezondheid, 1997.
20. Smans M, Muir CS, Boyle P. Atlas of Cancer Mortality in the European Economic Community. Lyon: IARC, 1992.
21. Holland WW, EC Working Group on Health Services and Avoidable Deaths. European Community Atlas of "Avoidable Deaths". Commission of the European Communities. Oxford: Oxford University Press, 1997.
22. Rutstein D, Berenberg W, Chalmers R. Measuring the quality of medical care. N Engl J Med 1976;297:582-8.
23. Lagasse R, Humblet PC, Hooft P, Van de Voorde H, Wollast E. Atlas of avoidable death in Belgium, 1980-1984. Arch Public Health 1992;50:1-97.
24. La Vecchia C, Lucchini F, Negri E, Boyle P, Maisonneuve P, Levi F. Trends of cancer mortality in Europe, 1955-1989. III: Breast and genital sites. Eur J Cancer 1992;28A:927-98.
25. Levi F, Lucchini F, Negri E, Franceschi S. La Vecchia C. Cervical cancer mortality among young women in Europe: Patterns and trends. Eur J Cancer 2000;36:2266-71.
26. Devesa SS, Silverman DT, Young JL, Pollack ES, Brown CC, Horm JW, Percy CL, Myers MH, McKay FW, Fraumeni JF. Cancer incidence and mortality trends among whites in the United States, 1947-84. J Natl Cancer Inst 1987;79:701-45.
27. Swerdlow A, dos Santos LR, Doll R. Cancer Incidence and Mortality in England and Wales: Trends and Risk Factors. Oxford: Oxford University Press, 2001.
28. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002;38:99-166.
29. Arbyn M, Van Oyen H. Secondary prevention of cervical cancer in Flanders: Facts and propositions for a structural approach. Memorandum Addressed to the Minister of Welfare, Public Health and Equal Chances and the Administration of Health Care of the Flemish Community [in Dutch]. WIV/EPI-series 20. Brussels: Scientific Institute of Public Health, 1999.
30. Macgregor JE, Campbell MK, Mann EM, Swanson KY. Screening for cervical intraepithelial neoplasia in northeast Scotland shows fall in incidence and mortality from invasive cancer with concomitant rise in preinvasive disease. BMJ 1994;308:1407-11.
31. Anttila A, Nieminen P. Cervical cancer screening programme in Finland. Eur J Cancer 2001;36:2209-14.
32. van Ballegooijen M, Hermens R. Cervical cancer screening in the Netherlands. Eur J Cancer 2000;36:2244-6.
33. Szarewski A, Cuzick J. Smoking and cervical neoplasia: A review of the evidence. J Epidemiol Biostat 1998;3:229-56.
34. Arbyn M, Van Oyen H. Cervical cancer screening in Belgium. Eur J Cancer 2000;36:2191-7.
35. Zakelj MP, Kirn VP, Skrlec F, Selb J. Can we rely on cancer mortality data? Checking the validity of cervical cancer mortality data for Slovenia. Radiol Oncol 2002;35:243-7.
36. zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol 1994;186:131-56.
37. Munoz N. Human papilloma virus and cervical cancer: Epidemiological evidence. In: Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Oxford: Blackwell, 1997. 3-13.
38. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
39. Moreno V, Bosch FX, Munoz N, Meijer CJLM, Shah KV, Walboomers JMM, Herrero R, Franceschi S. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: The IARC Multicentric Case-Control Study. Lancet 2002;359:1085-192.
40. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2002;37:4-66.
41. De Schryver A. Does screening for cervical cancer affect incidence and mortality trends? The Belgian experience. Eur J Cancer Clin Oncol 1989;25:395-9.
42. Giard RWM, Coebergh JWW, Wijnen JA. Causes of low effectiveness of population screening for cervical cancer. Ned Tijdschr Geneeskd 1996;141:317-21.
43. Raffle AE, Alden B, Mackenzie EFD. Detection rates for abnormal cervical smears: What are we screening for? Lancet 1995;345:1469-73.
44. Raffle AE. Deaths from cervical cancer began falling before screening programmes were established. BMJ 1997;315:953-4.
45. Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: Association with organised screening programmes. Lancet 1987;1:1247-9.
46. Hill GB, Adelstein AM. Cohort mortality from carcinoma of the cervix. Lancet 1967;2:605-6.
47. Yule R. Mortality from carcinoma of the cervix. Lancet 1978;1031-3.
48. Cook GA, Draper GJ. Trends in cervical cancer and carcinoma in situ in Great Britain. Br J Cancer 1984;50:367-75.
49. Austoker J. Cancer prevention in primary care. Screening for cervical cancer. BMJ 1994;309:241-8.
50. Anderson CM, Thornton JG. Screening for cervical cancer. Graphs may mislead. BMJ 1994;309:953-4.
51. Armstrong B, Holman D. Increasing mortality from cancer of the cervix in young Australian women. Med J Aust 1981;1:460-2.
52. Cox B, Skegg DC. Trends in cervical cancer in New Zealand. N Z Med J 1986;99:795-8.
53. van der Graaf Y, Zielhuis GA, Vooijs GP. Cervical cancer mortality in the Netherlands. Int J Epidemiol 1988;17:270-6.
54. Kirn VP, Kovacic J, Primic Zakelj M. Epidemiological evaluation of cervical cancer screening in Slovenia up to 1986. Eur J Gynaecol Oncol 1992;13:75-82.
55. Llorca J, Prieto MD. Delgado-Rodriguez M. Increase in cervical cancer mortality in Spain, 1951-1991. J Epidemiol Community Health 1999;53:408-11.
56. Anttila A, Pukkala E, Soderman B, Kallio M, Nieminen P, Hakama M. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: Recent increase in cervical cancer incidence. Int J Cancer 1999;83:59-65.
57. Chamberlain J. Failures of the cervical cytology screening programme. BMJ 1984;289:853-4.
58. Patnick J. Cervical cancer screening in England. Eur J Cancer 2000;36:2205-8.
59. Quinn M, Babb P, Jones J. Effect of screening on incidence and mortality from cancer of the cervix in England: Evaluation based on routinely collected statistics. BMJ 1999;318:904-8.
60. Sasieni P, Cuzick J, Farmery E. Accelerated decline in cervical cancer mortality in England and Wales. Lancet 1995;346:1566-7.
61. Sasieni P, Adams J. Effect of screening on cervical cancer mortality in England and Wales: Analysis of trends with an age period cohort model. BMJ 1999;318:1244-5.
62. Sasieni PD, Adams J. Analysis of cervical cancer mortality and incidence data from England and Wales: Evidence of a beneficial effect of screening. J R Stat Soc A 2000;163:191-209.
63. Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the "PSA era". Int J Cancer 2001;92:893-8.
64. Rostgaard K, Vaeth M, Holst H, Madsen M, Lynge E. Age-period-cohort modelling of breast cancer incidence in the Nordic countries. Stat Med 2001;20:47-61.
65. van Ballegooijen M, van den Akker van Marle ME, Patnick J, Lynge E, Arbyn M, Anttila A, Ronco G, Habbema DF. Overview of important cervical cancer screening process values in EU countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur J Cancer 2000;36:2177-88.
66. Arbyn M, Van Oyen H. Cost-analysis of cervical cancer screening in the Flemish region: The spontaneous versus the organised approach. Eur J Cancer 1997;33:15-6.
67. Arbyn M, Temmerman M. Belgian Parliament calls for organised cervical cancer screening and HPV research throughout Europe. Lancet Oncol 2002;3:74.